A Study of Vedolizumab With and Without Upadacitinib in Adults With Crohn's Disease
This study is investigating a new treatment approach for adults living with moderate to severe Crohn's Disease. Researchers want to find out if using two medicines together, vedolizumab and upadacitinib, is more effective at reducing inflammation and ulcers in the bowel than using vedolizumab by itself. They will also carefully monitor the safety of this combination treatment. For the first 12 weeks, all participants will receive vedolizumab along with either upadacitinib or an inactive dummy treatment (placebo). Those who respond well will then continue on vedolizumab alone for nearly a year. The study involves regular clinic visits and aims to advance our understanding of how to best treat Crohn's Disease.
نظرة سريعة
ما هو موضوع هذه الدراسة؟
This research study is for adults who have Crohn's Disease that is moderately to severely active. The main goal is to explore whether combining two medications, called vedolizumab and upadacitinib, works better than vedolizumab alone to help reduce inflammation and ulcers in the bowel. Researchers will also be carefully watching for any side effects and how safe the treatments are.
For the first 12 weeks, everyone in the study will receive vedolizumab. Half of the participants will also receive upadacitinib, and the other half will receive a placebo, which looks like upadacitinib but has no active medicine. This helps researchers compare the combination treatment with vedolizumab by itself. After these 12 weeks, if a participant's Crohn's disease shows a good response, they will then continue with vedolizumab alone for about 40 more weeks.
Understanding how different treatments work, alone or in combination, is crucial for improving care for people with Crohn's Disease. This study could help doctors make more informed decisions about the best ways to manage this condition in the future.
النقاط الرئيسية
- Tests vedolizumab with and without a second drug, upadacitinib.
- For adults with moderate to severe Crohn's Disease.
- Aims to reduce bowel inflammation and ulcers.
- Involves 15 clinic visits over about 70 weeks.
- Participants may receive a placebo in the initial phase.
- Careful monitoring of safety and effectiveness.
من قد يكون مؤهلاً؟
To join this study, you must be an adult between 18 and 65 years old with Crohn's Disease that has been diagnosed for at least three months. Your Crohn's disease must be considered moderately to severely active, and you should have signs of inflammation in your bowel, confirmed by special scans or tests.
It's important that previous treatments for your Crohn's disease, such as steroids, immune-suppressing drugs, or other biological medicines, haven't worked well enough for you, or you couldn't tolerate them.
There are also reasons why you might not be able to join. For example, if you have a different bowel condition like ulcerative colitis, or if you currently have a serious infection. Also, if you have certain complications from Crohn's Disease that might need surgery soon, such as blocked bowels or abscesses, or if you have severe kidney or liver problems, you wouldn't be able to take part.
هل يمكن أن تناسبك هذه الدراسة؟
أجب عن هذه الأسئلة السريعة لترى ما إذا كنت مؤهلاً. هذا دليل فقط - الفريق البحثي هو الذي يتخذ القرار النهائي.
- هل عمرك بين 18 و 65 سنة؟
- Do you have a confirmed diagnosis of moderately to severely active Crohn's Disease?
- Have other Crohn's treatments not worked well for you or caused problems?
- Do you currently have a serious infection or severe kidney/liver problems?
- Do you have any severe complications from Crohn's that might need surgery soon?
ماذا يتضمن المشاركة؟
If you join this study, you'll be involved for about 70 weeks, which is roughly a year and four months. For the first 12 weeks, you'll receive a combination of medicines (vedolizumab plus either upadacitinib or a placebo). If your condition improves significantly, you'll then switch to receiving vedolizumab by itself for the next 40 weeks. After finishing the treatment, there will be a follow-up period of about 18 weeks to check on your health and safety. You will need to visit the study clinic about 15 times over the course of the study for check-ups and assessments.
المخاطر والفوائد المحتملة
Locations (138)
- مركز UCSD الطبيالرمز البريدي المؤكدلا جولا، الولايات المتحدة· لم يبدأ التوظيف بعد
- Keck Medicine Of USC - USC Healthcare Center 1الرمز البريدي المؤكدلوس أنجلوس، الولايات المتحدة· لم يبدأ التوظيف بعد
- جمعية بيك لأمراض الجهاز الهضميالرمز البريدي المؤكدكولورادو سبرينغز، الولايات المتحدة· التوظيف
- GI PROS, Inc.الرمز البريدي المؤكدنابولي، الولايات المتحدة· نشط غير مجند
- Orlando Health Ambulatory Care Centerالرمز البريدي المؤكدأورلاندو، الولايات المتحدة· نشط غير مجند
- USF Health Morsani Center for Advanced Healthcareالرمز البريدي المؤكدتامبا، الولايات المتحدة· نشط غير مجند
- Indiana University (IU) Health University Hospitalالرمز البريدي المؤكدإنديانابوليس، الولايات المتحدة· نشط غير مجند
- University of Kentuckyالرمز البريدي المؤكدLexington, United States· نشط غير مجند
- Mount Sinai Hospital - The Susan and Leonard Feinstein Inflammatory Bowel Disease (IBD) Clinical Centerالرمز البريدي المؤكدنيويورك، الولايات المتحدة· نشط غير مجند
- Columbia University Medical Center, New York-Presbyterian Hospitalالرمز البريدي المؤكدنيويورك، الولايات المتحدة· لم يبدأ التوظيف بعد
- Lenox Hill Hospital Northwell Healthالرمز البريدي المؤكدنيويورك، الولايات المتحدة· نشط غير مجند
- Gastroenterology Associatesالرمز البريدي المؤكدغرينفيل، الولايات المتحدة· نشط غير مجند
أسئلة شائعة
What is Crohn's Disease?
Crohn's Disease is a long-term condition that causes inflammation in the digestive system, leading to symptoms like tummy pain, diarrhoea, and weight loss.
What are vedolizumab and upadacitinib?
These are medicines used to treat inflammatory conditions like Crohn's Disease by targeting specific parts of the immune system to reduce inflammation.
ماذا يعني مصطلح 'بلاسيبو'؟
A placebo is an inactive substance or treatment that looks the same as the real medicine but contains no active drug. It helps researchers compare the effects of the active medicine.
كم ستستغرق مدة الدراسة؟
The entire study will last for approximately 70 weeks, which is about one year and four months.
Will I know which treatment I am receiving?
During the first 12 weeks, you won't know if you're receiving upadacitinib or the placebo along with vedolizumab. This is standard in studies to ensure fair comparison of treatments.
كيفية معرفة المزيد
اتصل بتاكيدا
تحدث دائمًا إلى طبيبك العام أو الأخصائي قبل اتخاذ قرار بالمشاركة في دراسة.
هل أنت مهتم بالمشاركة؟
نقاش
مناقشة المجتمع
مدعوم من منتدانا في community.patient.info. يرجى التحلي بالاحترام — هذه ليست نصيحة طبية.